Hypomagnesaemia in oncologic patients: To treat or not to treat?

Magnesium Research

Volumn 22, Issue 1, 2009, Pages 5-9

  Wolf, Federica I ^a   Trapani, Valentina ^a   Cittadini, Achille ^a   Maier, Jeanette A M ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Angiogenesis; Cetuximab; Chemotherapy; Cisplatin; Metastasis; Tumor growth

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; MAGNESIUM; MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; HUMAN; MAGNESIUM DEFICIENCY; NEOPLASM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MAGNESIUM; MAGNESIUM DEFICIENCY; NEOPLASMS;

EID: 66149105860     PISSN: 09531424     EISSN: 19524021     Source Type: Journal    
DOI: 10.1684/mrh.2009.0157     Document Type: Article

References (31)

1. Wolf FI, Maier JA, Nasulewicz A, et al. Magnesium and neoplasia: from carcinogenesis to tumor growth and progression or treatment. Arch Biochem Biophys. 2007; 458: 24-32.
2. Wolf FI, Trapani V, Cittadini A. Magnesium and the con- trol of cell proliferation: looking for a needle in a hay- stack. Magnesium Res 2008; 21: 83-91.
3. Macaulay VM, Begent RH, Phillips ME, Newlands ES. Prophylaxis against hypomagnesaemia induced by cis- platinum combination chemotherapy. Cancer Che- mother Pharmacol 1982; 9: 179-81.
4. Mavichak V, Coppin CM, Wong NL, Dirks JH, Walker V, Sutton RA. Renal magnesium wasting and hypocalciuria in chronic cis-platinum nephropathy in man. Clin Sci (Lond) 1988; 75: 203-7.
5. Mune T, Yasuda K, Ishii M, Matsunaga T, Miura K. Tet- any due to hypomagnesemia induced by cisplatin and doxorubicin treatment for synovial sarcoma. Intern Med 1993; 32: 434-7.
6. Evans TR, Harper CL, Beveridge IG, Wastnage R, Mansi JL. A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continu- ous infusion 5-fluorouracil. Eur J Cancer 1995; 31 A: 174-8.
7. Al-Tweigeri T, Magliocco AM, DeCoteau JF. Cortical blindness as a manifestation of hypomagnesemia sec- ondary to cisplatin therapy: case report and review of literature. Gynecol Oncol 1999; 72: 120-2.
8. Hodgkinson E, Neville-Webbe HL, Coleman RE. Magne- sium depletion in patients receiving cisplatin-based che- motherapy. Clin Oncol (R Coll Radiol) 2006; 18: 710-8.
9. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007; 334: 115-24.
10. Atsmon J, Dolev E. Drug-induced hypomagnesaemia : scope and management. Drug Saf 2005; 28: 763-88.
11. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab Therapy and Symptomatic Hypomagnesaemia. JNatl Cancer Inst 2005; 97: 1221-4.
12. Fakih MG, Wilding G, Lombardo J. Cetuximab-induced hypomagnesaemia in patients with colorectal cancer. Clin Colorectal Cancer 2006; 6: 152-6.
13. Perrin C, Fabre C, Raoul JL, Boucher E. Behavioral disorders secondary to profound hypomagnesaemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesaemia due to cetuximab treatment. Ada Oncol 2006; 45: 1135-6.
14. Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007; 8: 387-94.
15. Groenestege WM, Thébault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes iso- lated recessive renal hypomagnesaemia. J Clin Invest 2007; 117: 2260-7.
16. Cao G, Hoenderop JG, Bindels RJ. Insight into the molecular regulation of the epithelial magnesium chan- nel TRPM6. Curr Opin Nephrol Hypertens 2008; 17: 373-8.
17. Nasulewicz A, Wietrzyk J, Wolf FI, et al. Magnesium deficiency inhibits primary tumor growth but favors metastasis in mice. Biochim Biophys Acta 2004; 1739: 26-32.
18. Vincenzi B, Santini D, Tonini G. Biological interaction between anti-epidermal growth factor receptor agent cetuximab and magnesium. Exp Opin Pharmacother 2008; 9: 1267-9.
19. Vincenzi B, Santini D, Galluzzo S, et al. Early magne- sium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res 2008; 14: 4219-24.
20. Wolf FI, Cittadini A, Maier JAM. Magnesium and tumors: ally or foe? Cancer Treat Rev 2009 (Epub 7 Feb. 2009).
21. Mpl in normal but not in transformed mammary epi- thelial cells. J Cell Physiol 1999; 180: 245-54.
22. Wolf FI, Trapani V. Cell (Patho) physiology of Magne- sium. Clin Sci 2008; 114: 27-35.
23. Maier JAM, Nasulewicz-Goldeman A, Simonacci M, Boninsegna A, Mazur A, Wolf FI. Insights into the mechanisms involved in magnesium-dependent inhibi- tion of primary tumor growth. Nutr Cancer 2007; 59: 192-8.
24. Maier JAM. Malpuech-Brugere C, Zimowska W, Rayssi- guier Y, Mazur A. Low magnesium promotes endothe- lial dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochim Biophys Ada 2004; 1689: 13-24.
25. Mazur A, Maier JAM, Rock E, Gueux E, Nowacki W, Rayssiguier Y. Magnesium and the inflammatory response: potential physiopathological implications. Arch Biochem Biophys. 2007; 458: 48-56.
26. Kerbel RS. Tumor angiogenesis. New Engl J Med 2008; 358: 2039-49.
27. Bernardini D, Nasulewicz A, Mazur A, Maier JAM. Mag- nesium and microvascular endothelial cells: a role in inflammation and angiogenesis. Frontiers Biosci 2005; 10: 1177-82.
28. Kobayashi H, Boelte KC, Lin PC. Endothelial cell adhe- sion molecules and cancer progression. Curr Med Chem 2007; 14: 377-86.
29. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004; 431: 405-6.
30. Song Y, Li TY, van Dam RM, Manson JE, Hu FB. Mag- nesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women. Am J Clin Nutr 2007; 85: 1068-74.
31. Rodríguez-Morán M, Guerrero-Romero F. Serum mag- nesium and C-reactive protein levels. Arch Dis Child 2008; 93: 676-80.